Plain-English translation of NCT04499053 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small Cell Lung research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immune-boosting drugs— and —given together with standard chemotherapy to treat advanced lung cancer in people living with HIV. The goal is to see whether this medication combination can help the immune system fight the cancer more effectively. The study will enroll 18 patients and monitor how well the treatment works and how safe it is.
People with HIV have historically been excluded from cancer trials, leaving a gap in treatment options for those who develop lung cancer. This medication combination has shown promise in other lung cancer patients, and this trial aims to determine whether it's safe and effective for people living with HIV whose virus is well-controlled.
You likely qualify if…
You likely don't qualify if…
You will receive four cycles of treatment (each cycle lasting 3 weeks), during which you'll get standard chemotherapy combined with the two immune-boosting medications through infusions. After these initial four cycles, if your cancer responds well or remains stable, you'll continue with maintenance treatment using one of the medications, possibly alternating with additional chemotherapy depending on your cancer type. Throughout the trial, you'll have regular clinic visits for blood tests, imaging scans, and safety monitoring.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States